Literature DB >> 17186710

Parkinson's disease: diagnosis and treatment.

Shobha S Rao1, Laura A Hofmann, Amer Shakil.   

Abstract

Parkinson's disease is a common neurodegenerative disorder that can cause significant disability and decreased quality of life. The cardinal physical signs of the disease are distal resting tremor, rigidity, bradykinesia, and asymmetric onset. Levodopa is the primary treatment for Parkinson's disease; however, its long-term use is limited by motor complications and drug-induced dyskinesia. Dopamine agonists are options for initial treatment and have been shown to delay the onset of motor complications. However, dopamine agonists are inferior to levodopa in controlling motor symptoms. After levodopa-related motor complications develop in advanced Parkinson's disease, it is beneficial to initiate adjuvant therapy with dopamine agonists, catechol O-methyltransferase inhibitors, or monoamine oxidase-B inhibitors. Deep brain stimulation of the subthalamic nucleus has been shown to ameliorate symptoms in patients with advanced disease. Depression, dementia, and psychosis are common psychiatric problems associated with Parkinson's disease. Psychosis is usually drug induced and can be managed initially by reducing antiparkinsonian medications. The judicious use of psychoactive agents may be necessary. Consultation with a subspecialist is often required.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17186710

Source DB:  PubMed          Journal:  Am Fam Physician        ISSN: 0002-838X            Impact factor:   3.292


  29 in total

1.  Evaluation of the neurotoxic/neuroprotective role of organoselenides using differentiated human neuroblastoma SH-SY5Y cell line challenged with 6-hydroxydopamine.

Authors:  Fernanda Martins Lopes; Giovana Ferreira Londero; Liana Marengo de Medeiros; Leonardo Lisbôa da Motta; Guilherme Antônio Behr; Valeska Aguiar de Oliveira; Mohammad Ibrahim; José Cláudio Fonseca Moreira; Lisiane de Oliveira Porciúncula; João Batista Teixeira da Rocha; Fábio Klamt
Journal:  Neurotox Res       Date:  2012-01-20       Impact factor: 3.911

2.  Case files of the program in medical toxicology at brown university: amantadine withdrawal and the neuroleptic malignant syndrome.

Authors:  Eric Brantley; Jamieson Cohn; Kavita Babu
Journal:  J Med Toxicol       Date:  2009-06

Review 3.  Drug-induced urinary retention: incidence, management and prevention.

Authors:  Katia M C Verhamme; Miriam C J M Sturkenboom; Bruno H Ch Stricker; Ruud Bosch
Journal:  Drug Saf       Date:  2008       Impact factor: 5.606

Review 4.  Continuous drug delivery in early- and late-stage Parkinson's disease as a strategy for avoiding dyskinesia induction and expression.

Authors:  P Jenner; A C McCreary; D K A Scheller
Journal:  J Neural Transm (Vienna)       Date:  2011-09-01       Impact factor: 3.575

5.  Toxic effects of nicotinamide methylation on mouse brain striatum neuronal cells and its relation to manganese.

Authors:  Yayoi Mori; Akiko Sugawara; Masayoshi Tsuji; Takeyasu Kakamu; Satoshi Tsuboi; Hideyuki Kanda; Takehito Hayakawa; Tetsuhito Fukushima
Journal:  Environ Health Prev Med       Date:  2012-01-15       Impact factor: 3.674

6.  Chinese medicine for idiopathic Parkinson's disease: A meta analysis of randomized controlled trials.

Authors:  Wei Wei; Hai-Yong Chen; Wen Fan; Shui-Fen Ye; Yi-Hui Xu; Jing Cai
Journal:  Chin J Integr Med       Date:  2016-10-27       Impact factor: 1.978

Review 7.  The therapeutic potential of interleukin-10 in neuroimmune diseases.

Authors:  A J Kwilasz; P M Grace; P Serbedzija; S F Maier; L R Watkins
Journal:  Neuropharmacology       Date:  2014-11-04       Impact factor: 5.250

Review 8.  Cognition, language, and clinical pathological features of non-Alzheimer's dementias: an overview.

Authors:  Jamie Reilly; Amy D Rodriguez; Martine Lamy; Jean Neils-Strunjas
Journal:  J Commun Disord       Date:  2010-05-06       Impact factor: 2.288

9.  Clinical features and 123I-FP-CIT SPECT imaging in drug-induced parkinsonism and Parkinson's disease.

Authors:  Francisco J Diaz-Corrales; Salome Sanz-Viedma; David Garcia-Solis; Teresa Escobar-Delgado; Pablo Mir
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-10-28       Impact factor: 9.236

Review 10.  Medical management of levodopa-associated motor complications in patients with Parkinson's disease.

Authors:  Joseph Jankovic; Mark Stacy
Journal:  CNS Drugs       Date:  2007       Impact factor: 5.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.